MHRA Chief Executive update to MHRA staff on the Pathways clinical trial

As with all clinical trials, the MHRA's top priority is the safety and wellbeing of the trial participants.

Following the update published on 27 February 2026, we are publishing, for transparency, a copy of an email sent to all MHRA staff by Chief Executive Lawrence Tallon on 11 March 2026, regarding the Pathways clinical trial.

A copy of the email is available here: MHRA staff email - 11 March 2026 (PDF, 125 KB, 2 pages)